- Natalizumab treatment for multiple sclerosis: updated recommendations for patient selection and monitoring2011 | 1. lékařská fakulta
- Natalizumab treatment for multiple sclerosis: recommendations for patient selection and monitoring2007 | 1. lékařská fakulta
- Natalizumab treatment for multiple sclerosis: recommendations for patient selection and monitoring2007 | Fakulta tělesné výchovy a sportu
- Infusion-related hypersensitivity reactions during natalizumab treatment2006 | 1. lékařská fakulta
- CD4+ T-cells counts and TH1/Th2 cytokine production after natalizumab treatment in multiple sclerosis patientsPublikace bez příslušnosti k fakultě
- Natalizumab in the treatment of pediatric multiple sclerosis2012 | Publikace bez příslušnosti k fakultě
- Distinct shift in immune cells counts and cerebrospinal fluid oligoclonal bands number after natalizumab treatment in multiple sclerosisPublikace bez příslušnosti k fakultě
- Progresivní multifokální leukoencefalopatie u nemocné s roztroušenou sklerózou léčenou natalizumabem2013 | 3. lékařská fakulta
- Zahájení léčby interferonem beta v nevhodné fázi nemoci2013 | 1. lékařská fakulta
- Long-term effectiveness of natalizumab on MRI outcomes and no evidence of disease activity in relapsing-remitting multiple sclerosis patients treated in a Czech Republic real-world setting: A longitudinal, retrospective study2020 | 1. lékařská fakulta
- Natalizumab Induces Changes of Cerebrospinal Fluid Measures in Multiple Sclerosis2021 | 1. lékařská fakulta, Fakulta tělesné výchovy a sportu
- Risk stratification for progressive multifocal leukoencephalopathy in patients treated with natalizumab2012 | 1. lékařská fakulta
- Cloning of the first human anti-JCPyV/VP1 neutralizing monoclonal antibody: Epitope definition and implications in risk stratification of patients under natalizumab therapy2014 | Přírodovědecká fakulta
- Effect of natalizumab on disease progression in secondary progressive multiple sclerosis (ASCEND): a phase 3, randomised, double-blind, placebo-controlled trial with an open-label extension2018 | 1. lékařská fakulta
- Fingolimod v reálné klinické praxi2017 | 1. lékařská fakulta
- Comparative effectiveness in multiple sclerosis: A methodological comparison2023 | 1. lékařská fakulta
- Additional efficacy endpoints from pivotal natalizumab trials in relapsing-remitting MS2012 | 1. lékařská fakulta
